Get the Stockscreener App
78.35
2.65%
2.02
After Hours:
78.20
-0.15
-0.19%
Overview
News
Price History
Option Chain
Financials
Why CVS Down?
Discussions
Forecast
Stock Split
Dividend History
Cvs Health Corp stock is traded at $78.35, with a volume of 7.08M.
It is up +2.65% in the last 24 hours and down -2.91% over the past month.
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It operates a top-tier health insurer (acquired through Aetna) through which it serves about 27 million medical members. The acquisition of Oak Street Health added primary care services to the mix, which could have significant synergies with all existing business lines.
See More
Previous Close:
$76.33
Open:
$76.37
24h Volume:
7.08M
Relative Volume:
0.88
Market Cap:
$99.46B
Revenue:
$393.94B
Net Income/Loss:
$428.00M
P/E Ratio:
204.78
EPS:
0.3826
Net Cash Flow:
$6.29B
1W Performance:
+5.14%
1M Performance:
-2.91%
6M Performance:
+23.35%
1Y Performance:
+44.45%
1-Day Range:
$76.19
$78.96
1-Week Range:
$73.40
$78.96
52-Week Range:
$53.36
$85.15
Cvs Health Corp Stock (CVS) Company Profile
Name
Cvs Health Corp
Sector
Industry
Phone
(401) 765-1500
Address
ONE CVS DR., WOONSOCKET
Compare CVS vs UNH, CI, ELV, HUM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVS
Cvs Health Corp
|
78.35 | 96.90B | 393.94B | 428.00M | 6.29B | 0.3826 |
|
UNH
Unitedhealth Group Inc
|
276.65 | 243.26B | 447.57B | 12.81B | 16.08B | 13.19 |
|
CI
Cigna Group
|
292.05 | 74.96B | 216.66B | 6.25B | 7.44B | 22.19 |
|
ELV
Elevance Health Inc
|
338.98 | 73.84B | 199.13B | 5.66B | 3.17B | 25.11 |
|
HUM
Humana Inc
|
193.94 | 23.28B | 126.36B | 1.30B | 1.55B | 10.67 |
Cvs Health Corp Stock (CVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-25 | Initiated | Goldman | Buy |
| Aug-18-25 | Upgrade | UBS | Neutral → Buy |
| Aug-14-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-13-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-12-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jan-30-25 | Upgrade | Edward Jones | Hold → Buy |
| Dec-03-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Nov-18-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-10-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-04-24 | Upgrade | TD Cowen | Hold → Buy |
| May-30-24 | Initiated | Robert W. Baird | Neutral |
| May-07-24 | Downgrade | TD Cowen | Buy → Hold |
| May-02-24 | Downgrade | UBS | Buy → Neutral |
| May-01-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-01-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-06-24 | Initiated | Barclays | Equal Weight |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Dec-22-23 | Initiated | HSBC Securities | Buy |
| Sep-19-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-12-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Aug-18-23 | Downgrade | Edward Jones | Buy → Hold |
| May-26-23 | Initiated | Piper Sandler | Overweight |
| Apr-21-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-03-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-23-22 | Resumed | Morgan Stanley | Overweight |
| Jun-17-22 | Initiated | Loop Capital | Buy |
| May-27-22 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Mar-29-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-11-22 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-14-21 | Initiated | Goldman | Buy |
| Dec-01-21 | Initiated | Seaport Research Partners | Buy |
| May-19-21 | Initiated | Wells Fargo | Equal Weight |
| Mar-17-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-08-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-17-20 | Initiated | Piper Sandler | Overweight |
| Jul-01-20 | Initiated | SVB Leerink | Mkt Perform |
| May-14-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-27-19 | Resumed | RBC Capital Mkts | Outperform |
| Sep-12-19 | Initiated | Deutsche Bank | Buy |
| Jun-05-19 | Upgrade | Standpoint Research | Hold → Buy |
| Apr-29-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-18-19 | Initiated | Guggenheim | Buy |
| Apr-15-19 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-10-19 | Reiterated | BofA/Merrill | Buy |
| Mar-13-19 | Initiated | Bernstein | Outperform |
| Feb-20-19 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jan-17-19 | Initiated | UBS | Buy |
| Dec-18-18 | Initiated | Barclays | Overweight |
| Nov-29-18 | Resumed | Goldman | Neutral |
| Nov-28-18 | Initiated | Evercore ISI | Outperform |
| Oct-26-18 | Resumed | Wolfe Research | Peer Perform |
| Jul-09-18 | Upgrade | Citigroup | Neutral → Buy |
| Feb-27-18 | Resumed | BofA/Merrill | Buy |
| Feb-13-18 | Reiterated | Citigroup | Neutral |
View All
Cvs Health Corp Stock (CVS) Latest News
CVS (CVS) Accepts TrumpRx Discount Cards for Prescription Drugs - GuruFocus
CVS Health (CVS) Embraces TrumpRx Discount Cards for Medication Savings - GuruFocus
CVS Pharmacy now accepting TrumpRx discount cards - Investing.com
TrumpRx drug discounts now available at 9,000 CVS pharmacies - stocktitan.net
CVS Expands Biosimilar Access to Lower Drug Costs - intellectia.ai
CVS Caremark Replaces Amgen And Eli Lilly's Branded Drugs, Expands Biosimilar Strategy For Weak Bone Disorder - Benzinga
CVS Specialty brings empathy and expertise to fertility patients - CVS Health
A Look Into CVS Health Inc's Price Over Earnings - Benzinga
CVS Faces Medicaid Network Loss And PBM Scrutiny As Valuation Looks Undemanding - simplywall.st
Aetna, a CVS Health company, receives Health Plan of the Year Award from Press Ganey - CVS Health
Why Press Ganey named Aetna its first Health Plan of the Year - stocktitan.net
CVS Health (CVS) Expands Biosimilar Offerings to Cut Costs - GuruFocus
FTC Settlement With Cigna's Pharmacy Benefit Manager Promises Cheaper Insulin, Boosts Dividend On Strong Quarterly Earnings - Benzinga
CVS Health to swap Amgen and Lilly’s bone drugs with biosimilars in commercial formularies - Seeking Alpha
CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists - Reuters
Is CVS Health Stock a Bad-News Buy? - AOL.com
Is CVS Health Stock a Bad-News Buy? - The Motley Fool
UnitedHealth, CVS, Humana Face Double Trouble As Trump's Medicare Cuts Are Just The Start—PBM 'Spread Pricing' Comes Under Fire - Yahoo Finance
New CVS drug list swaps Prolia for cheaper osteoporosis shots - stocktitan.net
Aetna launches simplified, digital-first, benefits onboarding experience for members in 2026 - CVS Health
CVS Health (CVS) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance Australia
Cigna settles FTC insulin case, aims to lower drug prices - WTAQ
Express Scripts Reaches Deal With FTC Over Insulin Pricing Practices - PYMNTS.com
Cigna settles FTC insulin case, commits to overhauling drug pricing - CNBC
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
UNH Stock: The Factors Behind UnitedHealth's Struggles in Its Recovery - intellectia.ai
Exclusive: Cigna settles FTC insulin case, aims to lower drug prices - Reuters
Four drugs to watch in 2026 that could reshape treatment options - CVS Health
Wegmans, CVS add SNAP/EBT payments on DoorDash - NJBIZ
Exclusive-Cigna settles FTC insulin case, commits to overhauling drug pricing - Bitget
CVS Health: Exploit The Sector Panic Ahead Of Earnings (NYSE:CVS) - Seeking Alpha
CVS Health (CVS) Expected to Beat Earnings Estimates: Should You Buy? - Finviz
CVS Health’s (CVS) Path Forward: Policy Challenges, Analyst Views, and Dividend Stability - Insider Monkey
CVS Health's (CVS) Path Forward: Policy Challenges, Analyst Views, and Dividend Stability - Finviz
CVS Pharmacy: How America’s Most Convenient Drugstore Quietly Became a Daily-Life Lifesaver - AD HOC NEWS
Shorts Report: How does CVS Health Corporation correlate with Nasdaq2025 Winners & Losers & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
CVS Health Corporation (CVS) Positioned for Long-Term Growth Amid Policy Shifts - Finviz
CVS Health Faces Antitrust Scrutiny As Valuation Flags Undervaluation Risk - Yahoo Finance UK
Argus Trims CVS Health (CVS) PT to $90 Amid Medicare Advantage Rate Uncertainty - Finviz
National Pension Service Purchases 119,189 Shares of CVS Health Corporation $CVS - MarketBeat
Looking Into CVS Health Corp's Recent Short Interest - Benzinga
AustralianSuper Pty Ltd Sells 492,309 Shares of CVS Health Corporation $CVS - MarketBeat
AE Wealth Management LLC Has $19.39 Million Stock Position in CVS Health Corporation $CVS - MarketBeat
US Labor Department proposes rule to boost transparency in pharmacy benefit manager fees - AOL.com
CVS Health Corporation $CVS Shares Sold by New York State Common Retirement Fund - MarketBeat
Novare Capital Management LLC Has $398,000 Stake in CVS Health Corporation $CVS - MarketBeat
CVS Health Corporation $CVS Shares Sold by Bank of New York Mellon Corp - MarketBeat
CVS Health and Merck Stocks Undervalued, 2026 Revenue Guidance of $400 Billion - Intellectia AI
CVS Health Corporation (NYSE:CVS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
CVS Pharmacy Review 2026: Why This Everyday Drugstore Is Quietly Becoming a Health Hub - AD HOC NEWS
CVS Health (CVS) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
Cvs Health Corp Stock (CVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
3.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):